6/4/2004

The Australian government cited national security considerations in refusing to release details of its no-bid, multi-million dollar purchase of an antiviral medicine stockpile for use in case of a flu pandemic. The government decided to purchase Tamiflu, rather than Relenza, which was developed by Biota, a small Melbourne biotech firm. Biota has filed suit against GlaxoSmithKline, alleging the company failed to adequately promote Relenza under a licensing agreement.

Related Summaries